eXmoor Pharma Concepts Ltd.. (11/16/23). "Press Release: eXmoor Appoints Matthew Paterson as First Chief Commercial Officer". Bristol.

	Organisation	eXmoor Pharma Concepts Ltd.
	Organisation 2	Quotient Sciences Ltd.
	Group	Quotient (Group)
	Product	cell and gene therapy manufacturing (CGT manufacturing)
	Product 2	contract manufacturing (biologicals)
	Person	Paterson, Matthew (eXmoor Pharma 202311– Chief Commercial Officer before over 18 years at Quotient Sciences)
	Person 2	Osborne, Angela (eXmoor Pharma 202302 CEO)

New CCO to apply experience growing US and UK business to support eXmoor’s expansion

eXmoor pharma, the full-service cell and gene therapy (CGT) manufacturing partner, announced the hiring of Matthew Paterson as the company’s first Chief Commercial Officer, to spearhead the company’s growth and international footprint as it expands its contract development and manufacturing services for CGTs. Paterson joins from Quotient Sciences, where he built and led the North American business development team, creating and executing the global marketing and brand strategy. Over 18 years at Quotient, he held a number of senior leadership positions and most recently served as VP of Corporate Strategy.

Paterson brings over 25 years of global expertise in building high-performance teams in successful life sciences businesses and contract development and manufacturing organizations (CDMOs). In the new role, he will be responsible for maintaining eXmoor’s rapid growth following the recent launch of its new Cell and Gene Therapy Center, a purpose-built 65,000 sq ft GMP manufacturing facility, to develop and manufacture autologous and allogeneic cell therapies, as well as viral vectors.

“I’m delighted to join eXmoor at this pivotal moment for a world leader in the CGT space,” said Paterson. “The wave of new cell and gene therapies in development hold so much potential for patients. It’s clear that our success will directly result in better patient access to life-changing advanced therapies.”

“Matthew completes the build out of our senior team. His experience will bolster eXmoor as we endeavor to meet the industry’s growing capacity needs, offering top-class expertise and cutting-edge capabilities along with true partnership,” said Angela Osborne, CEO of eXmoor. “In particular, Matthew’s experience as a driven and committed commercial leader will be crucial as we develop new relationships and begin GMP manufacturing in the new year.”

About eXmoor pharma

eXmoor pharma is a one-stop cell-and-gene-therapy partner accelerating the manufacturing journey from research to patients. Founded in 2004, eXmoor has specialized in the CGT sector since 2007, helping organizations to understand, plan and implement the appropriate CMC strategy. eXmoor does this via its combination of GMP manufacturing capability and its translation and capital consulting groups, including process and analytical development labs. eXmoor has completed over 500 projects for 150 organizations and is headquartered in Bristol, UK, with 80 current employees, growing to 200 by 2027. To learn more: exmoorpharma.com.

Media Contacts:

IB Communications
Tel +44 (0)20 89434685
exmoor@ibcomms.agency

Record changed: 2024-01-20